The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MIT engineers create nanoparticles for delivering personalized cancer vaccines• MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics• Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease• The Oral Delivery Challenge: Why It Requires More Than the Right Route• Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets•
Capsugel Lonza — A Better Way to Deliver Microbiome-Based Therapies
Evonik EUDRACAP colon - GMP quality targeted drug delivery from the upper small intestine to the ileo-colonic region

Editor's Choice

All Editor's Choice →
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
 Editor's Choice

Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

Prokarium’s live bacterial immunotherapy ZH9 aims to redefine the non-muscle invasive bladder cancer treatment paradigm, building upon the precedence of BCG with a product designed for real-world urology practice.

BY Nick Glanville, Livija Deban and Dara Henry · SEP 28, 2026 · 9 MIN READ
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026